AMG 172 First in Human Study in Patients With Kidney Cancer

Inclusion Criteria:

• Subjects must have a pathologically documented, definitively diagnosed, clear cell RCCthat is relapsed/refractory following at least two lines of systemic therapy (one ofwhich must be a tyrosine kinase), or the subject refuses standard therapy

• Measurable disease per RECIST 1.1 criteria. Subjects with non-measurable, butevaluable disease are also eligible for Part 1 of the study.

• Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1

• Willing to provide tumor samples and / or slides

• Hematological function, as follows:

1. Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L;

2. Platelet count ≥ 100 x 10^9/L;

3. Hemoglobin > 9 g/dL

• Prothrombin time (PT) or partial thromboplastin time (PTT) < 1.5 x institutional upperlimit of normal (IULN)

• Hepatic function, as follows:

1. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x ULN;

2. Total bilirubin < 1.5 x ULN (< 3.0 x ULN for subjects with documented Gilbert'sDisease or for whom the indirect bilirubin level suggests an extrahepatic sourceof elevation);

3. Alkaline phosphatase < 2 x ULN (< 5 x ULN in subjects whom the PI and sponsoragree that clinical data suggest extrahepatic source of elevation)

• Other inclusion criteria may apply

Exclusion Criteria:

• Known primary central nervous system (CNS) tumors or brain metastases

• History of bleeding diathesis

• Myocardial infarction within 6 months of study day 1, symptomatic congestive heartfailure (New York Heart Association > class II), unstable angina, or unstable cardiacarrhythmia requiring medication, or uncontrolled hypertension in the opinion of theinvestigator

• Clinically significant ECG changes which obscure the ability to assess the PR, QT, andQRS interval; congenital long QT syndrome

• A baseline ECG QTcF > 470 msec

• Known positive test for human immunodeficiency virus (HIV)

• Known acute or chronic hepatitis B or hepatitis C infection as determined by serologictests

• Other exclusion criteria may apply